Literature DB >> 18497073

Role of estrogens and their receptors in adhesion and invasiveness of breast cancer cells.

Marie Maynadier1, Philippe Nirdé, Jean-Marie Ramirez, Anne Marie Cathiard, Nadine Platet, Monique Chambon, Marcel Garcia.   

Abstract

Estrogen receptors (ERs) are overexpressed in human breast cancers (BCs) and associated with differentiated tumors and with a more favorable prognosis. Paradoxically, ERs mediate the mitogenic action of estrogens in human BC cells and the efficacy of antiestrogens in adjuvant therapy of primary tumors. The exact mechanism underlying the ER protection against cancer progression to metastasis remains to be investigated. Herein, we show that ERs decrease invasiveness of BC cells. Detailed studies revealed that the unliganded and the E2-activated ERs decrease cancer cell invasion in vitro through two distinct mechanisms. In the presence of ligand, ERalpha inhibits invasion through a mechanism requiring the functional ERalpha domains involved in the transcriptional activation of target genes. Moreover, using different approaches, we found that cell-cell contacts were markedly increased by 17beta-estradiol (E2) treatment and decreased by the pure antiestrogen, ICI182,780. This cell-cell adhesion was associated with an increase of the major intercellular junctions, desmosomes. Conversely, in the absence of ligand, ERalpha also inhibits invasion through a distinct mechanism involving protein-protein interaction with the region of the first zinc finger of ERalpha. The relationship of these data with clinical studies and their potential therapeutic consequences will be discussed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18497073      PMCID: PMC2566989          DOI: 10.1007/978-0-387-69080-3_48

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  29 in total

Review 1.  Estrogen receptor beta--a new dimension in estrogen mechanism of action.

Authors:  J A Gustafsson
Journal:  J Endocrinol       Date:  1999-12       Impact factor: 4.286

2.  Tamoxifen therapy for primary breast cancer and risk of contralateral breast cancer.

Authors:  C I Li; K E Malone; N S Weiss; J R Daling
Journal:  J Natl Cancer Inst       Date:  2001-07-04       Impact factor: 13.506

Review 3.  The nuclear receptor ligand-binding domain: structure and function.

Authors:  D Moras; H Gronemeyer
Journal:  Curr Opin Cell Biol       Date:  1998-06       Impact factor: 8.382

4.  Estradiol and fibulin-1 inhibit motility of human ovarian- and breast-cancer cells induced by fibronectin.

Authors:  Y Hayashido; A Lucas; C Rougeot; S Godyna; W S Argraves; H Rochefort
Journal:  Int J Cancer       Date:  1998-02-09       Impact factor: 7.396

5.  Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer.

Authors: 
Journal:  Lancet       Date:  1997-10-11       Impact factor: 79.321

6.  Unliganded and liganded estrogen receptors protect against cancer invasion via different mechanisms.

Authors:  N Platet; S Cunat; D Chalbos; H Rochefort; M Garcia
Journal:  Mol Endocrinol       Date:  2000-07

7.  Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer.

Authors:  B Fisher; J H Jeong; J Dignam; S Anderson; E Mamounas; D L Wickerham; N Wolmark
Journal:  J Natl Cancer Inst Monogr       Date:  2001

Review 8.  Estrogen receptor mediated inhibition of cancer cell invasion and motility: an overview.

Authors:  H Rochefort; N Platet; Y Hayashido; D Derocq; A Lucas; S Cunat; M Garcia
Journal:  J Steroid Biochem Mol Biol       Date:  1998-04       Impact factor: 4.292

9.  Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer.

Authors:  N Roodi; L R Bailey; W Y Kao; C S Verrier; C J Yee; W D Dupont; F F Parl
Journal:  J Natl Cancer Inst       Date:  1995-03-15       Impact factor: 13.506

View more
  17 in total

1.  Opposing effects of Runx2 and estradiol on breast cancer cell proliferation: in vitro identification of reciprocally regulated gene signature related to clinical letrozole responsiveness.

Authors:  Nyam-Osor Chimge; Sanjeev K Baniwal; Jingqin Luo; Simon Coetzee; Omar Khalid; Benjamin P Berman; Debu Tripathy; Matthew J Ellis; Baruch Frenkel
Journal:  Clin Cancer Res       Date:  2011-12-06       Impact factor: 12.531

2.  Acetylation targets HSD17B4 for degradation via the CMA pathway in response to estrone.

Authors:  Ye Zhang; Ying-Ying Xu; Chuan-Bo Yao; Jin-Tao Li; Xiang-Ning Zhao; Hong-Bin Yang; Min Zhang; Miao Yin; Jing Chen; Qun-Ying Lei
Journal:  Autophagy       Date:  2017-02-22       Impact factor: 16.016

3.  Loss of estrogen receptor 1 enhances cervical cancer invasion.

Authors:  Yali Zhai; Guido T Bommer; Ying Feng; Alexandra B Wiese; Eric R Fearon; Kathleen R Cho
Journal:  Am J Pathol       Date:  2010-06-25       Impact factor: 4.307

4.  Estrogen Receptor-Regulated Gene Signatures in Invasive Breast Cancer Cells and Aggressive Breast Tumors.

Authors:  Emily Smart; Svetlana E Semina; Luis H Alejo; Nidhi S Kansara; Jonna Frasor
Journal:  Cancers (Basel)       Date:  2022-06-09       Impact factor: 6.575

5.  Association of estrogen receptor α gene PvuII and XbaI polymorphisms with non-small cell lung cancer.

Authors:  Huai-Lu Chang; Yu-Jen Cheng; Chung-Kuang Su; Meng-Chih Chen; Fu-Hsin Chang; Fu-Gong Lin; Li-Feng Liu; Shyng-Shiou F Yuan; Ming-Chih Chou; Chien-Fu Huang; Chi-Chiang Yang
Journal:  Oncol Lett       Date:  2011-11-15       Impact factor: 2.967

6.  Regulation of breast cancer metastasis by Runx2 and estrogen signaling: the role of SNAI2.

Authors:  Nyam-Osor Chimge; Sanjeev K Baniwal; Gillian H Little; Yi-bu Chen; Michael Kahn; Debu Tripathy; Zea Borok; Baruch Frenkel
Journal:  Breast Cancer Res       Date:  2011-12-09       Impact factor: 6.466

Review 7.  Update on the Role of NFκB in Promoting Aggressive Phenotypes of Estrogen Receptor-Positive Breast Cancer.

Authors:  Emily Smart; Svetlana E Semina; Jonna Frasor
Journal:  Endocrinology       Date:  2020-10-01       Impact factor: 4.736

8.  Regulation of estrogen receptor signaling in breast carcinogenesis and breast cancer therapy.

Authors:  Zhuan Zhou; Joe X Qiao; Amit Shetty; George Wu; Yi Huang; Nancy E Davidson; Yong Wan
Journal:  Cell Mol Life Sci       Date:  2014-04       Impact factor: 9.207

9.  The exposure of breast cancer cells to fulvestrant and tamoxifen modulates cell migration differently.

Authors:  Dionysia Lymperatou; Efstathia Giannopoulou; Angelos K Koutras; Haralabos P Kalofonos
Journal:  Biomed Res Int       Date:  2013-07-02       Impact factor: 3.411

10.  Association of Biomarker Discrepancy and Treatment Decision, Disease Outcome in Recurrent/Metastatic Breast Cancer Patients.

Authors:  Yujie Lu; Yiwei Tong; Xiaosong Chen; Kunwei Shen
Journal:  Front Oncol       Date:  2021-07-01       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.